000028 国药一致
2025/03 - 三个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入18,293,519-4.17%74,378,49475,477,48573,443,13768,357,810
减:营业总成本17,881,473-4.01%73,017,47573,277,09771,309,68866,519,747
    其中:营业成本16,401,114-3.62%66,129,20966,425,42664,516,92660,339,298
               财务费用38,253-16.09%239,424204,535189,514212,483
               资产减值损失(1,791)-1.20%(994,532)(17,577)(71,588)(242,905)
公允价值变动收益----(20,675)(15,161)28,871--
投资收益79,519-22.60%241,793237,029139,131292,381
    其中:对联营企业和合营企业的投资收益100,213-9.17%369,703315,446298,527333,397
营业利润439,138-19.28%573,4782,467,4252,306,0691,952,411
利润总额438,327-20.34%575,4692,473,2272,311,0701,974,853
减:所得税费用90,650-12.94%338,466514,739539,332447,211
净利润347,677-22.07%237,0041,958,4871,771,7381,527,642
减:非控股权益19,679-65.69%(405,490)359,231285,030191,214
股东净利润327,998-15.63%642,4931,599,2561,486,7081,336,428

市场价值指针
每股收益 (元) *0.590-15.71%1.1502.8702.6703.120
每股派息 (元) *----0.3660.6800.8000.600
每股净资产 (元) *32.3371.09%31.74731.29037.66634.861
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容